Redumed consists of L-Carnitine, Sibutramine.
L-Carnitine - Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The "vitamin BT" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Levocarnitine can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.
1) Used to improve immunity in children and adultIncrease phagocytosis of granulocytes, increase stimulation of the T – lympfocytes induced by phytohemagglutinin and membrane activation of NK Cells ( Natural killer cells ) So, it has +ve influence on certain parameters of the immune system.2) Redumed (L-Carnitine) has a significant increase effect in peripheral blood supply and capacity dilatation as a result, oxygen absorption rise especially during exercise. 2)Used in cases of B – thalassemiaL-carnitine stabilizes red blood cells and supplementation may decrease the need for blood transfusions. 3) Improve lung functions in chronic lung diseases4) Used in fat loss management, chronic fatigue syndrome and athletic performance.5) L- Carnitine Supplementation In Athletes6) Research shows that people who supplement with Redumed (L-Carnitine) while engaging in an exercise regimen are less likely to experience muscle soreness.5 However, the belief that carnitine’s effect on energy release will help build muscle.7) Redumed (L-Carnitine) and Fat Loss:L-Carnitine is "the most important nutrient for naturally supporting the weight loss process,"8) Heart and Circulation Benefits of Redumed (L-Carnitine) :Supplemental Redumed (L-Carnitine) has been associated with significantly higher concentrations of pyruvate, ATP and creatine phosphate in portions of the heart muscle during conditions of extreme stress. Similarly, in tests upon peripheral circulation, Redumed (L-Carnitine) was found to be quite useful for supporting normal blood flow.
Sibutramine - Redumed (Sibutramine) was withdrawn from the U.S. market in October 2010.
Redumed (Sibutramine) affects chemicals in the brain that affect weight maintenance.
Redumed (Sibutramine) is used together with diet and exercise to treat obesity that may be related to diabetes, high cholesterol, or high blood pressure.
Redumed (Sibutramine) may also be used for other purposes not listed in this medication guide.
Redumed (Sibutramine) is an drug for the treatment of central action obesity. The mechanism of action is due to selective inhibition of serotonin reuptake of norepinephrine and, to a lesser extent, of dopamine. This medication accelerates the onset and prolong satiety, which leads to a decrease in food consumption. It increases energy expenditure by stimulating thermogenesis mediated by activation of beta3-adrenergic receptors. Acts on both sides of the balance of energy and helps reduce body weight.
Redumed (Sibutramine) and its metabolites did not release monoamines, and they are not MAO inhibitors, have no affinity for serotonergic, adrenergic, dopaminergic, muscarinic, histamine, benzodiazepine and NMDA receptors.
Redumed (Sibutramine) is an orally administered agent for the treatment of obesity. Redumed (Sibutramine) exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin and norepinephrine reuptake in vivo, but not in vitro. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both in vitro and in vivo. In human brain tissue, M1 and M2 also inhibit dopamine reuptake in vitro, but with ~3-fold lower potency than for the reuptake inhibition of serotonin or norepinephrine. Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic actions. In addition, receptor binding profiles show that sibutramine, M1 and M2 have low affinity for serotonin (5-HT1, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C), norepinephrine (b, b1, b3, a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors. These compounds also lack monoamine oxidase inhibitory activity in vitro and in vivo.
Adult: Initially, 10 mg daily in the morning. Re-evaluate treatment in patients whose weight loss is <2 kg in the 1 st 4 wk of treatment. May increase dose to 15 mg daily. Reassess 4 wk later. Discontinue treatment if weight loss is still <2 kg. Max: 15 mg daily.